- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07946601
Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Laura Bukavina, MD, MPH, MSc
- Telefonnummer: (216) 444-6043
- E-post: bukavil2@ccf.org
Studera Kontakt Backup
- Namn: Myra Krnac
- Telefonnummer: (216)444-1047
- E-post: krnacm@ccf.org
Studieorter
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- Cleveland Clinic Foundation
-
Kontakt:
- Laura Bukavina, MD, MPH, MSc
- Telefonnummer: (216) 444-6043
- E-post: bukavil2@ccf.org
-
Huvudutredare:
- Laura Bukavina, MD, MPH, MSc
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
- Planned for radical cystectomy with curative intent.
- Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
- Adequate organ function as defined by standard laboratory criteria.
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Evidence of clinical node-positive or metastatic disease (cN+ or cM1) on baseline imaging.
- Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
- Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
- Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ctDNA-negative MIBC
There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments. |
Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Recurrence free survival (RFS)
Tidsram: 2 years
|
RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first. |
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall survival (OS)
Tidsram: at 2 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 2 years
|
|
Overall survival
Tidsram: at 5 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 5 years
|
|
Rate of pathological complete response (pCR)
Tidsram: at day 0
|
To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy. |
at day 0
|
|
Rates of surgical morbidity
Tidsram: up to 4 weeks
|
To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Rates of complications
Tidsram: up to 4 weeks
|
To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Positive predictive value
Tidsram: days -42 to 0
|
To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
|
Negative predictive value
Tidsram: days -42 to 0
|
To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Laura Bukavina, MD, MPH, MSc, The Cleveland Clinic
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- CASE9826
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
There is not currently an intention or plan to share IPD
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .